{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:12Z","timestamp":1707525192920},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,8]]},"DOI":"10.7759\/cureus.41581","type":"journal-article","created":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T01:34:26Z","timestamp":1688866466000},"source":"Crossref","is-referenced-by-count":0,"title":["De Novo Pure Erythroid Leukemia With Rapid Progression and Multiple Lytic Bone Lesions: A Case Report"],"prefix":"10.7759","author":[{"given":"Shoichiro","family":"Okazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24626","article-title":"Pure erythroid leukemia","volume":"92","author":"Wang W","year":"2017","unstructured":"Wang W, Wang SA, Medeiros LJ, Khoury JD. Pure erythroid leukemia. Am J Hematol. 2017, 92:292-6. 10.1002\/ajh.24626","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100773","article-title":"Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved","volume":"47","author":"Shallis RM","year":"2021","unstructured":"Shallis RM, Gale RP, Lazarus HM, et al.. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. 2021, 47:100773. 10.1016\/j.blre.2020.100773","journal-title":"Blood Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.175","article-title":"De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity","volume":"31","author":"Reinig EF","year":"2018","unstructured":"Reinig EF, Greipp PT, Chiu A, Howard MT, Reichard KK. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Mod Pathol. 2018, 31:705-17. 10.1038\/modpathol.2017.175","journal-title":"Mod Pathol"},{"key":"ref4","article-title":"Acute myeloid back leukemia","author":"Miyazaki Y","year":"2020","unstructured":"Miyazaki Y. Acute myeloid back leukemia. Japanese Society of Hematology. Guidelines for the Treatment of Hematopoietic Tumors (2018 Revised Edition). Kanehara Publishing, Tokyo; 2020. 12-13."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.11.027","article-title":"Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy","volume":"39","author":"Erba HP","year":"2015","unstructured":"Erba HP. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res. 2015, 39:183-91. 10.1016\/j.leukres.2014.11.027","journal-title":"Leuk Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea DA","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, et al.. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021, 96:208-17. 10.1002\/ajh.26039","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00746-x","article-title":"Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases","volume":"12","author":"Reichard KK","year":"2022","unstructured":"Reichard KK, Tefferi A, Abdelmagid M, Orazi A, Alexandres C, Haack J, Greipp PT. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood Cancer J. 2022, 12:147. 10.1038\/s41408-022-00746-x","journal-title":"Blood Cancer J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.032","article-title":"Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 3. Acute myeloid leukemia presenting with lytic bone lesions","volume":"22","author":"Johnson JL","year":"2004","unstructured":"Johnson JL, Moscinski L, Zuckerman K. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 3. Acute myeloid leukemia presenting with lytic bone lesions. J Clin Oncol. 2004, 22:2968-70. 10.1200\/JCO.2004.09.032","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2015.017","article-title":"Osteolytic bone lesions - a rare presentation of AML M6","volume":"7","author":"Geetha N","year":"2015","unstructured":"Geetha N, Sreelesh KP, Priya MJ, Lali VS, Rekha N. Osteolytic bone lesions - a rare presentation of AML M6. Mediterr J Hematol Infect Dis. 2015, 7:e2015017. 10.4084\/MJHID.2015.017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.02715.x","article-title":"Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions","volume":"68","author":"Muler JH","year":"2002","unstructured":"Muler JH, Valdez R, Hayes C, Kaminski MS. Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions. Eur J Haematol. 2002, 68:392-6. 10.1034\/j.1600-0609.2002.02715.x","journal-title":"Eur J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861115)58:10<2273::aid-cncr2820581019>3.0.co;2-e","article-title":"Osteolytic tumors in acute megakaryoblastic leukemia","volume":"58","author":"Dharmasena F","year":"1986","unstructured":"Dharmasena F, Wickham N, McHugh PJ, Catovsky D, Galton DA. Osteolytic tumors in acute megakaryoblastic leukemia. Cancer. 1986, 58:2273-7. 10.1002\/1097-0142(19861115)58:10&lt;2273::aid-cncr2820581019&gt;3.0.co;2-e","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25437","article-title":"Pure erythroid leukemia: the value of E-cadherin in making the diagnosis","volume":"94","author":"Caldwell I","year":"2019","unstructured":"Caldwell I, Ruskova A, Royle G, Liang J, Bain BJ. Pure erythroid leukemia: the value of E-cadherin in making the diagnosis. Am J Hematol. 2019, 94:726-7. 10.1002\/ajh.25437","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2938","article-title":"Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways","volume":"68","author":"Onder TT","year":"2008","unstructured":"Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68:3645-54. 10.1158\/0008-5472.CAN-07-2938","journal-title":"Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/163005-de-novo-pure-erythroid-leukemia-with-rapid-progression-and-multiple-lytic-bone-lesions-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:33Z","timestamp":1707508953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/163005-de-novo-pure-erythroid-leukemia-with-rapid-progression-and-multiple-lytic-bone-lesions-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.41581","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,8]]}}}